Clinical Trials in Mauritius

There are about 19 clinical studies being (or have been) conducted in Mauritius.
The country of the clinical trial is determined by the location of where the clinical research is being studied.
Most studies are often held in multiple locations & countries.

this study extension objective is to evaluate the safety and tolerability of a 200-mcg dose
every 4 weeks for 24 weeks of IPP-201101 in patients with active systemic lupus erythematosus
(SLE) who had participated in the main study IP-005.

STUDY OBJECTIVE To confirm the incidence of in-hospital postoperative complications in adult
surgical patients in Africa.
STUDY DESIGN Seven day, African national multi-centre prospective observational cohort study
of adult (≥18 years) patients undergoing surgery. Patients will be followed up for a maximum
of 30 days. We will follow the original International Surgical Outcomes Study (ISOS) study
design.
The primary outcome is in-hospital postoperative complications in adult surgical patients in
Africa. Secondary outcomes include in-hospital mortality and the relationship between
postoperative complications and postoperative mortality.
The intention is to present a representative sample of surgical outcomes across all African
countries. This study will run between February and March 2016.

Non-alcoholic steatohepatitis, abbreviated as NASH, is a chronic liver disease that may
progress to cirrhosis. The disease is mostly associated with obesity and type 2 diabetes
mellitus, or insulin resistance and is very common. However, Treatment of NASH is a
significant unmet clinical need.
IVA337 (lanifibranor) is a next generation pan-PPAR (peroxisome proliferator-activated
receptors) agonist addressing the pathophysiology of NASH : metabolic, inflammatory and
fibrotic.
The purpose of this research is to evaluate the efficacy and the safety of two doses of
IVA337 (800mg, 1200 mg) per day for 24 weeks versus placebo in adult NASH patients with liver
steatosis and moderate to severe necroinflammation without cirrhosis.

M2951 is an investigational drug under evaluation for treatment of autoimmune and
inflammatory disorders. The purpose of the study is to assess the Safety and Efficacy of
M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

This is a multicenter open-label, prospective study in subjects with dark skin from one of
the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American and with
moderate to severe acne vulgaris on the face.
All eligible subjects will receive Adapalene 0.3% - BPO 2.5% gel (Epiduo Forte/TactuPump
Forte) once daily on whole face.
The purpose of this trial is to evaluate subject reported outcomes with the combination of
Adapalene 0.3% - BPO 2.5%, Epiduo Forte / TactuPump Forte gel, after 16 weeks of treatment of
moderate to severe acne in dark skin phototypes (IV to VI).

The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination
with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or
GT2 or GT3 chronic hepatitis C (CHC) infection.

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The data & information found on this website is provided “AS IS” from ClinicalTrials.gov.
Neither we, the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.